|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of Helicobacter pylori infection in atrophic gastritis显示文摘Helicobacter pylori(Hp) is a major human pathogen causing chronic, progressive gastric mucosal damage and is linked to gastric atrophy and cancer. Hp-positive individuals constitute the major reservoir for transmission of infection. There is no ideal treatment for Hp. Hp infection is not cured by a single antibiotic, and sometimes, a combined treatment with three or more antibiotics is ineffective. Atrophic gastritis(AG) is a chronic disease whose main features are atrophy and/or intestinal metaplasia of the gastric glands, which arise from long-standing Hp infection. AG is reportedly linked to an increased risk for gastric cancer, particularly when extensive intestinal metaplasia is present. Active or past Hp infection may be detected by conventional methods in about two-thirds of AG patients. By immunoblotting of sera against Hp whole-cell protein lysates, a previous exposure to Hp infection is detected in all AG patients. According to guidelines, AG patients with Hp positivity should receive eradication treatment. The goals of treatment are as follows:(1) Cure of infection, resolution of inflammation and normalization of gastric functions;(2) possible reversal of atrophic and metaplastic changes of the gastric mucosa; and(3) prevention of gastric cancer. An ideal antibiotic regimen for Hp should achieve eradication rates of approximately 90%, and complex multidrug regimens are required to reach this goal. Amongst the factors associated with treatment failure are high bacterial load, high gastric acidity, Hp strain, smoking, low compliance, overweight, and increasing antibiotic resistance. AG, when involving the corporal mucosa, is linked to reduced gastric acid secretion. At a non-acidic intra-gastric p H, the efficacy of the common treatment regimens combining proton pump inhibitors with one or more antibiotics may not be the same as that observed in patients with Hp gastritis in an acid-producing stomach. Although the efficacy of these therapeutic regimens has been thoroughly tested in subjects with Hp infection, there is a paucity of evidence in the subgroupof patients with AG. Bismuth-based therapy may be an attractive treatment in the specific setting of AG, and specific studies on the efficacy of bismuth-based therapies are needed in patients with AG. | Edith Lahner Marilia Carabotti Bruno Annibale | 2018 | World Journal of Gastroenterology2018，24，22： | 57 |
| 2 | Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery显示文摘The present review summarizes the prevalence and active clinical problems in obese patients with Helicobacter pylori(H.pylori)infection,as well as the outcomes after bariatric surgery in this patient population.The involvement of H.pylori in the pathophysiology of obesity is still debated.It may be that the infection is protective against obesity,because of the gastritis-induced decrease in production and secretion of the orexigenic hormone ghrelin.However,recent epidemiological studies have failed to show an association between H.pylori infection and reduced body mass index.H.pylori infection might represent a limiting factor in the access to bariatric bypass surgery,even if highquality evidence indicating the advantages of preoperative H.pylori screening and eradication is lacking.The clinical management of infection is complicated by the lower eradication rates with standard therapeutic regimens reported in obese patients than in the normalweight population.Prospective clinical studies to ameliorate both H.pylori eradication rates and control the clinical outcomes of H.pylori infection after different bariatric procedures are warranted. | Marilia Carabotti Chiara D'Ercole Angelo Iossa Enrico Corazziari Gianfranco Silecchia Carola Severi | 2014 | World Journal of Gastroenterology2014，20，3： | 3 |
| 3 | Impact of Laparoscopic Sleeve Gastrectomy on Upper Gastrointestinal Symptoms显示文摘 | Marilia Carabotti Gianfranco Silecchia Francesco Greco Frida Leonetti Luca Piretta Marco Rengo Mario Rizzello John Osborn Enrico Corazziari Carola Severi | 2013 | Obesity Surgery2013，，10： | 1 |
| 4 | The gut-brain axis: interactions between enteric microbiota, central and en- teric nervous systems显示文摘 | Carabotti M Seirocco A Maselli MA | 2015 | Ann Gastroenterol2015，28，2： | 1 |
| 5 | The gut-brain axis : interactions between enteric mi-crobiota ,central and enteric nervous systems显示文摘 | CARABOTTI M SCIROCCO A MASELLI M A etal | 2015 | An-nals Gastroenteroloy2015，28，2： | 1 |
| 6 | The gut-brain axis:interactions between enteric microbiota, central and enteric nervous systems显示文摘 | Carabotti M Scirocco A Maselli MA | 2015 | Ann Gastroenterol2015，28，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员